Amylyx Pharmaceuticals (NASDAQ:AMLX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.82) by 20.73 percent. The company reported quarterly sales of $21.89 million which beat the analyst consensus estimate of $4.72 million by 363.67 percent.
Henry Schein Affirms FY22 Adj. EPS Guidance
Affirms full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91, reflecting growth of 7% to 10% over full-year 2021 GAAP diluted EPS and growth
